Evidence review

BPC-157 Benefits: What the Research Actually Shows

BPC-157 is sold for tendon repair, gut healing, muscle recovery and joint pain. Each of those claims traces back to a real body of research. Almost none of it was conducted in people.

  • 36Studies included in the 2025 systematic review, from 544 screened
  • 35Of those 36 that were preclinical rather than clinical
  • 12Patients in the single clinical study, which was retrospective
  • 2028When the first randomised controlled trial is due to complete

The short version

The benefits attributed to BPC-157 are real findings from real studies. The catch is what those studies were: rats and mice, not people. As of the most recent systematic review, no completed randomised controlled trial in humans had established that BPC-157 does any of the things it is sold for.

That is not a debunking. Animal results are how every medicine starts, and the BPC-157 literature is more substantial than most compounds sold in this market can claim. But there is a specific step between an animal result and a claim about a person, and for BPC-157 that step has not been taken yet. It is being taken right now, for the first time, and we cover that trial below.

What a systematic review of the whole literature found

In 2025, researchers at Case Western Reserve University and University Hospitals Cleveland published a systematic review of BPC-157 in HSS Journal. They searched PubMed, Cochrane and Embase from database inception to 3 June 2024, screened in three phases with two reviewers, and checked PROSPERO for unpublished reviews. This is the most complete accounting of the evidence that currently exists.

They identified 544 articles published between 1993 and 2024. After removing duplicates and screening, 36 studies met inclusion criteria. Thirty-five were preclinical. One was clinical.

What the review concluded

“This systematic review of level IV and level V studies suggests that BPC-157 shows promise for promoting recovery from musculoskeletal injuries.”

Read that sentence closely, because it is doing two things at once. It says promise, which is genuine and positive. And it says level IV and level V, which is the bottom of the evidence hierarchy — case series, case reports, expert opinion and animal work. There is no level I or level II evidence for BPC-157 to review, which is why the authors did not review any.

The claimed benefits, one at a time

Here is what each of the four main claims rests on, according to the review. In every case the underlying evidence is animal work, so the honest framing is what was observed in models, not what BPC-157 does for you.

  • Tendon and ligament healing. The most-cited application. In preclinical models the review reports improved functional, structural and biomechanical outcomes following tendon and ligament injury. Biomechanical here means the repaired tissue was physically tested, which is a meaningful measure rather than an impression of recovery — in animals.
  • Muscle injury. The same pattern of improved functional, structural and biomechanical outcomes in muscle injury models. This is the claim the first randomised trial is now testing in people, which tells you the researchers designing that trial regarded it as the most promising place to start.
  • Bone and fracture. Also covered by the review’s finding of improved outcomes in bony injuries in preclinical models. The volume of work here is smaller than for soft tissue.
  • Gut and mucosal healing. The oldest claim, and the origin of the compound — BPC-157 is derived from a protein found in gastric juice, and the peptide is described as promoting mucosal integrity. This is where the research programme began in the early 1990s. It is also outside the scope of the orthopaedic review above, so we have not assessed the gut literature systematically and are not going to characterise its strength here.

The one human study, in full

Of the 36 studies, exactly one involved people. It is small enough to describe completely in a paragraph, which is itself the point.

It was a retrospective study of musculoskeletal pain following intraarticular injection of BPC-157 for unspecified chronic knee pain. Twelve patients. Seven of them reported relief lasting more than six months.

Worth knowing

Retrospective means the researchers looked back at people who had already been treated, rather than deciding in advance who would receive what. There was no placebo group and no randomisation, so nothing in the result separates the peptide from the natural course of the condition, the injection itself, or expectation.

Seven of twelve people feeling better is not nothing, and we are not dismissing it. It is a reason to run a proper trial. It is not a result you can generalise from, and the condition treated was recorded as unspecified, which limits what could be concluded even if the design had been stronger. The United States Anti-Doping Agency puts the overall position bluntly: “There are no human clinical trials establishing efficacy for the use of BPC-157 for any diagnosis or treatment.”

The first real trial is running now

This is the part of the story that has changed recently, and most pages on this subject have not caught up with it. In February 2026 a Phase 2 trial began recruiting: “A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI.”

It is sponsored by Hudson Biotech and running at Peking University Shenzhen Hospital in China, with 120 participants planned. Injuries are confirmed by MRI rather than by examination alone, and the primary outcomes are time to return to unrestricted sport at eight weeks, and the change in MRI-assessed injury volume. Secondary outcomes include pain during activity, strength symmetry measured by dynamometry, and a functional scale.

That is a serious design. Randomised, double-blind, placebo-controlled, with objective imaging as an endpoint rather than self-report alone. If BPC-157 accelerates soft-tissue healing in people, this is the kind of study that would show it — and if it does not, this is the kind of study that would show that too.

When we will know

Primary completion is estimated for February 2027 and final completion for February 2028. Until then the trial is evidence that the question is being asked properly, not evidence of an answer.

We will log the result on the regulatory tracker when it publishes, whichever way it goes, and update this page accordingly.

How it is proposed to work

The review describes three mechanisms suggested by the studies it examined: BPC-157 enhances growth hormone receptor expression, acts on several pathways involved in cell growth and angiogenesis, and reduces inflammatory cytokines. Angiogenesis — the formation of new blood vessels — is the one most often invoked to explain healing effects, since tissue that gets better blood supply tends to repair faster.

A plausible mechanism is worth having, but it is not evidence of benefit. Many compounds with coherent mechanisms have failed in trials, which is the entire reason trials are run rather than reasoned around. A mechanism tells you why something might work. It does not tell you whether it does.

One pharmacokinetic detail is worth carrying away: the review reports a plasma half-life of under 30 minutes, with hepatic metabolism and renal clearance. Any claim about how a particular product delivers sustained effects has to contend with that number.

Two things that sit alongside any benefit

A page about benefits is incomplete without the other side of the ledger, so briefly: BPC-157 has no established human safety profile, and it is prohibited in tested sport.

The same systematic review that found promise also found no clinical safety data at all, and its authors note that adverse effects remain possible through unregulated manufacturing and contamination. The single registered human safety trial has never published its results. We set all of that out on our BPC-157 side effects page.

And the World Anti-Doping Agency lists BPC-157 under S0, prohibited at all times in and out of competition. For a competing athlete, that consideration arrives before any question about whether it works. The overview page covers its regulatory position, including the FDA’s Category 2 listing.

What would change our assessment

We would rather state in advance what would move us than reserve the right to reinterpret later. Any of the following would change what this page says:

  • The hamstring trial publishes a positive result on its primary outcomes, with the MRI endpoint supporting the functional one.
  • The 2015 Phase 1 safety study publishes its adverse-event data, in either direction.
  • A second randomised controlled trial, independent of the first, reports on any indication.
  • The FDA moves BPC-157 off Category 2, or an advisory committee recommendation is published.

What will not change it: more animal studies, vendor testimonials, or practitioner case reports. Those are the categories of evidence that already exist in quantity, and adding to them does not answer the outstanding question.

Sources and method

  • The systematic review. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. Every study count, the level of evidence, the mechanisms, the half-life and the description of the single clinical study are taken from its abstract.
  • The Phase 2 trial. NCT07437547 on ClinicalTrials.gov, sponsored by Hudson Biotech. Design, enrollment, outcome measures, site and dates are read from that registry record.
  • The efficacy position. USADA on BPC-157, quoted directly for the statement about human clinical trials and for the S0 classification.
  • What we could not verify. We have read the systematic review’s abstract, not its full text, so we cannot characterise its risk-of-bias assessment or how the 35 preclinical studies were distributed across research groups. We have not conducted our own review of the gastrointestinal literature and have deliberately declined to grade it here. We have not seen any data from the Phase 2 trial, which is still recruiting.
  • Method. Figures come from the primary record — the published abstract and the trial registry — rather than from secondary coverage. Where a claim is supported only by animal work, this page says so in the same sentence as the claim rather than in a disclaimer at the bottom.

BPC-157 overview →   BPC-157 side effects →   How we source and verify →

Literature and registry sources checked 30 August 2026. We recheck this page when NCT07437547 reports.